Clinical Trial & R&D Data Management Software
The buyer population — Scientific research and development services
Base industry report for 5417 →- Establishments · CanadaA
- 3,088
- Under 10 employeesA
- 61%
- Establishments · USA
- 22,180
- Employment · USA
- 950,883
- Payroll · USA
- $142.6B
Of 3,088 Canadian establishments with employees, 61% have fewer than ten — mostly small operators. Each of those is one potential account, before any filter for size or fit.
Entry signal — what decides who wins here
Structure decidesThe binding constraint is not executional. Being better than the incumbent does not, by itself, get you in — this one is cleared with capital, an asset, or a permission.
Raise or borrow the entry ticket, or buy an operator who has already paid it. The barrier is money rather than permission, so it yields to a balance sheet — and an acquisition is usually cheaper than a start.
Measured, not forecast: the share of US establishments opening in one year that were still active later. It counts good operators and bad ones together, which is exactly why it is the honest answer to “what are the odds”. It is for the whole sector rather than this market, and the ten-year figure comes from an older cohort because no younger one has reached ten years.
This is not a probability of success, and it is not a verdict on you. No survival probability is published per market, and inventing one would be worse than saying so. What the bar reads is how much of the outcome sits inside an operator's control: green means the hurdles are ones a better operator clears, red means the binding constraint is capital, an asset or a permission rather than execution. Someone arriving with an advantage this screen did not assume can win a market shown in red.
Companies named in this market · 10
The binding constraint — entry cost
Validation is the moat and it is expensive: GxP computerised-system validation, 21 CFR Part 11 audit trails and sponsor qualification audits all sit ahead of the first paying trial, and sponsors buy suites rather than modules. Veeva's R&D and Quality business alone runs at $1.75B and IQVIA's technology segment at roughly $6.6B — an entrant is not competing for a seat but for a place in a validated stack.
Sectors joined: Deep Tech · Market Research/AI · AI Market Research · Materials · Research · Materials Science
[UNVERIFIED] Sector-to-NAICS mapping is analyst judgment — see data/angel-sector-map.json. Counts are a per-record cross-reference and are not additive across records.
The incumbent
Who owns this market and who is coming for it. Fields a screen never reached say so rather than guessing.
Financials & market size — sourced
Figures that came from a filing, a results release or reputable reporting, each carrying its evidence tier.
Market size, derived
Built from the competitor set upward rather than quoted from a forecast. Published TAMs in these categories are frequently reverse-engineered from each other, so any published figure is checked against the vendor arithmetic rather than trusted on its own.
Disclosed revenue from 2 of 4 named vendors. The market is at least this large.
No vendor has both a disclosed revenue and a published share.
Only a revenue floor is known — the true market is larger by whatever the undisclosed vendors earn.
Competitor set · 4 named · 2 disclose revenue
| Name | Revenue | Share | Note |
|---|---|---|---|
| Veeva Systems (R&D and Quality)NYSE: VEEVA | $1.7B | — | FY2026 segment revenue |
| IQVIA (Technology & Analytics Solutions)NYSE: IQVB | $6.6B | — | 2025, summed from four reported quarters; broader than CTMS — includes analytics and real-world data |
| Medidata (Dassault Systèmes)C | not disclosed | — | Not disclosed separately by Dassault |
| Oracle Health Sciences / Medable / CastorC | not disclosed | — | Oracle does not break out health sciences; Medable and Castor are private |
Startups & challengers
Newer and smaller vendors going at the incumbent — funded challengers first. Named, not researched to the depth of the field above; a company with a page here links to it.
| Company | Stage | What it does | Raised |
|---|---|---|---|
| Benchling | Funded challenger | Cloud R&D data platform (notebook, registry, workflows) for biotech and pharma labs | — |
| Reify Health | Funded challenger | Patient enrollment and site collaboration software for clinical trials | — |
| Veeva | Funded challenger | Cloud CRM, data and clinical software for pharma and biotech. | — |
| Kaleidoscope | Startup | Scientific data and project management for biotech R&D teams | — |
| CRIO ONLINE | Scrappy competitor | eSource and trial management software for clinical research sites and sponsors | — |
Evidence
Evidence. Incumbent financials and market-share figures on this record ARE sourced (tier A/B, see the financials block). The cut factor and reasoning remain analyst judgment and were not tested against customers.
Where the industry talks
The associations, forums and events where people in this trade actually talk shop — where to listen before entering, and where the first customers are found. Each link was opened on the date shown.
Individual members ('over 3,000') per its Our Story page. The professional body for the people who run EDC and CDMS systems; runs CCDM certification and the GCDMP.
Sept 14-17, 2026, Raleigh NC. The main clinical-data-management meeting; EMEA and India editions also run. No attendance figure published.
Individual members per its homepage ('member community of 22,000'). Site coordinators, CRAs and trial managers; has local chapters and discussion groups.
Global membership body for drug-development professionals; its DIA Global Annual Meeting (DIA 2027 already open for registration) is the largest eClinical vendor floor. No member count on its site.
Non-profit that sets the SDTM/ADaM/ODM data standards regulators require; member organisations, user networks and the annual US Interchange. No member count on its site.
National alliance of Canadian clinical research sites and networks; its Members page says 'nearly 200' member organisations. Has a Study Operations & Data Management committee.
Non-profit supporting Ontario's trial sector; runs CTO Stream (ethics review) and an annual conference (Nov 4-5, 2026, Toronto).
Blocked automated access (Cloudflare 403). Search results show a February 2026 issue and September 2026 articles; the trade magazine for trial-operations and eClinical technology.
SOCRA (socra.org) is live and holds its 35th annual meeting Sept 2026 but is a certification body for CRAs rather than a data-management venue. Reddit's r/clinicalresearch could not be verified (RSS returned 429) and is omitted.